Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

April 30, 2006

Conditions
Peritoneal DialysisChronic Kidney Disease
Interventions
DRUG

Sevelamer Hydrochloride (Renagel®)

Sevelamer hydrochloride three times per day with each meal

DRUG

Calcium acetate (PhosLo® )

Calcium acetate three times per day with each meal

Trial Locations (17)

B-3000

UZ Gasthuisberg, Leuven

DN-8200

Aarhus University Hospital, Århus N

DN-7000

Fredericia Sygehus, Fredericia

DN-2730

Copenhagen University Hospital, Herlev

FR-14033

CHRU Clémenceau, Caen

IT-90127

Ospedale civico e benfratelli, Palermo

IT-36100

Ospedale San Bortolo, Vicenza

NL-1105 AZ

AMC, Amsterdam

ES-28040

Fundacion Jimenez Diaz, Madrid

ES-28046

Hospital Universitario La Paz, Madrid

B15 2TH

University Hospital ,Queen Elizabeth Hospital, Birmingham

HP11 2TT

High Wycombe Hospital, Buckinghamshire

CF 14 4XN

University of Wales College of Medicine, Cardiff

G11 6NT

Glasgow Western Infirmary, Glasgow

E1 1BB

Royal Hospital The Royal London, London

MK6 5LD

Milton Keynes General Hospital, Milton Keynes

OX3 7LJ

The Churchill Hospital, Oxford Radcliffe Hospitals NHS Trust, Oxford

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00196755 - Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis | Biotech Hunter | Biotech Hunter